PCP-induced deficits in murine nest building activity: Employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia

Behavioural Brain Research

Volumn 273, Issue , 2014, Pages 63-72

  Pedersen, Christian Spang ^a   Sørensen, Dorte Bratbo ^b   Parachikova, Anna I ^a   Plath, Niels ^a  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

EVP 6124; Nest building test (NEST); Schizophrenia; Social interaction test (SIT); Sub chronic PCP; TC 5619

Indexed keywords

7-CHLORO-N-QUINUCLIDIN-3-YL-BENZO(B)THIOPHENE-2-CARBOXAMIDE; AMINO ACID RECEPTOR BLOCKING AGENT; BENZOFURAN DERIVATIVE; N-(2-(PYRIDIN-3-YLMETHYL)-1-AZABICYCLO(2.2.2)OCT-3-YL)-1-BENZOFURAN-2-CARBOXAMIDE; NEUROLEPTIC AGENT; PHENCYCLIDINE; QUINUCLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HYPERKINESIA; MALE; MOUSE; PSYCHOLOGY; ROTAROD TEST; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZOFURANS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; HYPERKINESIS; MALE; MICE; MICE, INBRED C57BL; PHENCYCLIDINE; QUINUCLIDINES; ROTAROD PERFORMANCE TEST; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; THIOPHENES;

EID: 84905638429     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.07.023     Document Type: Article

References (78)

1. Jablensky A., Sartorius N., Ernberg G., Anker M., Korten A., Cooper J.E., Day R., Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992, 20:1-97.
2. Carpenter W.T., Buchanan, Schizophrenia R.W. N Engl J Med 1994, 330:681-690.
3. Aleman A., Kahn R.S., Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 2003, 60:565-571.
4. McGrath J., Saha S., Welham J., El S.O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004, 2:13.
5. Shields L.B., Hunsaker D.M., Hunsaker J.C. III. Schizophrenia and suicide: a 10-year review of Kentucky medical examiner cases. J Forensic Sci 2007, 52:930-937.
6. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
7. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-564.
8. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999, 35:51-68.
9. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000, 321:1371-1376.
10. Tamminga C.A., Buchanan R.W., Gold J.M. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998, 13(Suppl 3):S21-S26.
11. EnVivo Pharmaceuticals EnVivo Pharmaceuticals Presents Positive Comprehensive Phase 2b Study Results in Schizophrenia at American College of Neuropsychopharmacology Annual Meeting 2011.
12. EnVivo Pharmaceuticals EnVivo Announces Positive Phase 2b Clinical Data in Schizophrenia: EVP-6124 Meets Primary Endpoint with Statistically Significant Improvement in Cognition and Multiple Secondary Endpoints for Improvement in Function and Impact on Negative Symptoms 2011, EnVivo Pharmaceuticals.
13. Targacept TC-5619 negative and cognetive dysfunctions in schizophrenia, innatentive-predominant in ADHD and Alzheimer's disease 2012, Targacept.
14. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder. Biol Psychiatry 2006, 59:1198-1207.
15. Kay S. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
16. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
17. Noda Y., Yamada K., Furukawa H., Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 1995, 116:2531-2537.
18. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 2004, 3:287-302.
19. Moreau J.L. Validation of an animal model of anhedonia, a core symptom of depression. Encephale-Revue de Psychiatrie Clinique Biologique et Therapeutique 1997, 23:280-289.
20. Gerlai R., Clayton N.S. Analysing hippocampal function in transgenic mice: an ethological perspective. Trends Neurosci 1999, 22:47-51.
21. Sarter M., Berntson G.G. Tapping artificially into natural talents. Trends Neurosci 1999, 22:300-301.
22. Crabbe J.C., Morris R.G.M. Festina lente: Late-night thoughts on high-throughput screening of mouse behavior. Nat Neurosci 2004, 7:1175-1179.
23. Tecott L.H., Nestler E.J. Neurobehavioral assessment in the information age. Nat Neurosci 2004, 7:462-466.
24. Arguello P.A., Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 2006, 52:179-196.
25. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 2005, 181:611-638.
26. Deacon R.M. Assessing hoarding in mice. Nat Protoc 2006, 1:2828-2830.
27. Deacon R.M., Raley J.M., Perry V.H., Rawlins J.N. Burrowing into prion disease. Neuroreport 2001, 12:2053-2057.
28. Lynch C.B., Hegmann J.P. Genetic differences influencing behavioral temperature regulation in small mammals. I. Nesting by Mus musculus. Behav Genet 1972, 2:43-53.
29. Roof R., Snyder B., Yabe Y., Zaleska M. Use of ethological rodent behavior to assess efficacy of potential drugs for Alzheimer's disease 2010.
30. Koh H.Y., Kim D., Lee J., Lee S., Shin H.S. Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1. Genes Brain Behav 2008, 7:120-128.
31. Lijam N., Paylor R., McDonald M.P., Crawley J.N., Deng C.X., Herrup K., Stevens K.E., Maccaferri G., Mcbain C.J., Sussman D.J., WynshawBoris A. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 1997, 90:895-905.
32. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., Caron M.G., Tonegawa S. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Nat Acad Sci USA 2003, 100:8987-8992.
33. EnVivo Pharmaceuticals Inc. EnVivo Confirms EVP-6124 Mechanism of Action 2011, EnVivo Pharmaceuticals Inc.
34. Prickaerts J., van Goethem N.P., Chesworth R., Shapiro G., Boes F.G., Methfessel C., Reneerkens O.A.H., Flood D.G., Hilt D., Gawryl M., Bertrand S., Bertrad D., Konig G.E.V.P-6124 a novel and selective a7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of a7 nicotinic acetylcholine receptors. Neuropharmacology 2012, 62:1099-1110.
35. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., WErsinger S.R., Hesse R.A., Stachowiak E.K., Stachowiak M.K., Papke R.L., Lippiello P.M., Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 2009, 78:803-812.
36. Goetghebeur P., Dias R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study. Psychopharmacology 2008, 202:287-293.
37. Pedersen C.S., Goetghebeur P., Dias R. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. J Neurosci Methods 2009, 185:66-69.
38. Deacon R.M. Assessing nest building in mice. Nat Protoc 2006, 1:1117-1119.
39. Lee K.W., Zhao X., Im J.Y., Grosso H., Jang W.H., Chan T.W., Sonsalla P.K., German D.C., Ichijo H., Junn E., Mouradian M.M. Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 2012, 7:e29935.
40. Siemen H., Colas D., Heller H.C., Brustle O., Pera R.A. Pumilio-2 function in the mouse nervous system. PLoS One 2011, 6:e25932.
41. Lopez M.E., Klein A.D., Dimbil U.J., Scott M.P. Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder. J Neurosci 2011, 31:4367-4378.
42. Oliver P.L., Davies K.E. Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. Hum Mol Genet 2009, 18:4576-4589.
43. Halene T.B., Ehrlichman R.S., Liang Y., Christian E.P., Jonak G.J., Gur T.L., Blendy J.A., Dow H.C., Brodkin E.S., Schneider F., Gur R.C., Siegel S.J. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 2009, 8:661-675.
44. Vitalo A., Fricchione J., Casali M., Berdichevsky Y., Hoge E.A., Rauch S.L., Berthiaume F., Yarmush M.L., Benson H., Fricchione G.L., Levine J.B. Nest making and oxytocin comparably promote wound healing in isolation reared rats. PLoS One 2009, 4:e5523.
45. Hess S.E., Rohr S., Dufour B.D., Gaskill B.N., Pajor E.A., Garner J.P. Home improvement: C57BL/6J mice given more naturalistic nesting materials build better nests. J Am Assoc Lab Anim Sci 2008, 47:25-31.
46. Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment Retard Dev Disabil Res Rev 2004, 10:248-258.
47. Ibi D., Takuma K., Koike H., Mizoguchi H., Tsuritani K., Kuwahara Y., Kamei H., Nagai T., Yoneda Y., Nabeshima T., Yamada K. Social isolation rearing-induced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice. J Neurochem 2008, 105:921-932.
48. Brain P.F., Ramirez J.M. Nest-building in rodents: a brief cross_species rewiew. Cross-disciplinary studies on aggresion 1986, 157-178. Publicaciones De La Universidad De Sivilla, Sevilla. P.F. Brain, J.M. Ramirez (Eds.).
49. Jones B.J., Roberts D.J. The quantiative measurement of motor inco-ordination in naive mice using an acelerating rotarod. J Pharm Pharmacol 1968, 20:302-304.
50. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994, 151:825-835.
51. Kane J.M. Risperidone. Am J Psychiatry 1994, 151:802-803.
52. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
53. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug; sernyl. Arch Neurol Psychiatry 1959, 81:363-369.
54. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
55. Intil T., Keskiner A., Kiremitci N., Holden J.M.C. Effect of phencyclidine in chronic schizophrenics. Can J Psychiatry 1967, 12:209-212.
56. Martin J.R., Berman M.H., Krewsun I., Small S.F. Phencyclidine-induced stereotyped behavior and serotonergic syndrome in rat. Life Sci 1979, 24:1699-1703.
57. Fletcher P.J., Tenn C.C., Rizos Z., Lovic V., Kapur S. Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) 2005, 183:190-200.
58. Handelmann G.E., Contreras P.C., O'Donohue T.L. Selective memory impairment by phencyclidine in rats. Eur J Pharmacol 1987, 140:69-73.
59. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 1996, 7:3-23.
60. Geyer M.A., Segal D.S., Greenberg B.D. Increased startle responding in rats treated with phencyclidine. Neurobehav Toxicol Teratol 1984, 6:161-164.
61. Winston-Salem N.C. Targacept announces positive top-line results from phase 2 trial of TC-5619 in cognitive dysfunction in schizophrenia 2011, Targacept.
62. Winston-Salem N.C. Targacept presents statistically significant results for TC-5619 on measures of cognitive dysfunction in schizophrenia and negative symptoms of schizophrenia 2011, Targacept.
63. Geyer M.A., Moghaddam B. Animal models relevant to schizophrenia disorders. Neuropsychopharmacology - 5th Generation of Progress 2002, 689-701. Lippincott, Williams, & Wilkins, Philadelphia, Pennsylvania, Chapter num. 50. K.L. Davis, D. Charnery, J.T. Coyle, C. Nemeroff (Eds.).
64. Barnes S.A., Der-Avakian A., Markou A. Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 2014, 24:744-758. 10.1016/j.euroneuro.2013.10.001.
65. Etherton M.R., Blaiss C.A., Powell C.M., Sudhof T.C. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Nat Acad Sci USA 2009, 106:17998-18003.
66. Kirov G., Gumus D., Chen W., Norton N., Georgieva L., Sari M., O'Donovan M.C., Erdogan F., Owen M.J., Ropers H.H., Ullmann R. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 2008, 17:458-465.
67. 2A/2C receptors. Eur J Pharmacol 2007, 564:123-130.
68. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 1992, 49:538-544.
69. Farde L., Nordstrom A.L., Nyberg S., Halldin C., Sedvall G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994, 55(Suppl B):67-69.
70. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
71. Geyer M.A., Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1071-1079.
72. Jackson D.M., Johansson C., Lindgren L.M., Bengtsson A. Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 1994, 48:465-471.
73. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41:1-24.
74. Karlsson R.M., Tanaka K., Saksida L.M., Bussey T.J., Heilig M., Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 2008.
75. Carlisle H.J., Luong T.N., Medina-Marino A., Schenker L., Khorosheva E., Indersmitten T., Gunapala K.M., Steele A.D., O'Dell T.J., Patterson P.H., Kennedy M.B. Deletion of densin-180 results in abnormal behaviors associated with mental illness and reduces mGluR5 and DISC1 in the postsynaptic density fraction. J Neurosci 2011, 31:16194-16207.
76. Hiroi N., Zhu H., Lee M., Funke B., Arai M., Itokawa M., Kucherlapati R., Morrow B., Sawamura T., Agatsuma S. A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice. Proc Nat Acad Sci U S A 2005, 102:19132-19137.
77. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1984, 52242. Department of Psychiatry College of Medicine, The University of Iowa, Iowa City, IA.
78. Winston-Salem N. Targacept Announces Negative Top-Line Results from Phase 2b Clinical Trial of TC-5619 in Schizophrenia 2013, Targacept.